Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naive Crohn’s disease cohort with penetrating disease, -ostomies and sarcopenia

ABSTRACT:

Background:

Ustekinumab was approved in 2016 for the treatment of moderate–severe Crohn’s disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use imaging techniques to predict response to biologics in CD.

Objectives:

We assessed the 2-year real-world effectiveness and safety of ustekinumab in a tertiary CD cohort with the use of novel imaging techniques.

Design:

Retrospective cohort study.

Methods:

Retrospective data were collected between 2016 and 2021. Study end points included ustekinumab persistence, biological and/or clinical response and remission at 12, 18 and 24 months. Statistical analysis included demographic and inferential analyses.

Res

SUBMITTER:  

PROVIDER: S-EPMC10434845 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature